Business News • PR NewsWire • Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes

Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes

Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular (CV) events associated with SYMLIN® (pramlintide acetate) inj

View More : http://www.prnewswire.com/news-releases/meta-analysis-of-symlinr-clinical-data-showed-no-increased-risk-of-cardiovascula...

Releted News by prnewswire

Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose

Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin

Film Independent Announces Jury Award Winners of 2010 Los Angeles Film Festival, Presented by The Los Angeles Times

Johnson & Johnson Pharmaceutical Research & Development Reports Phase 2b Clinical Trial Results Evaluating Canagliflozin to Treat Type 2 Diabetes